Literature DB >> 30911604

Pathophysiology and classification of pseudomyxoma peritonei.

Mark Bignell1, Norman J Carr, Faheez Mohamed.   

Abstract

Background: The term pseudomyxoma peritonei (PMP) was first described in 1884 and there has been much debate since then over the term. A recent consensus of world experts agreed that PMP should be thought of as a clinical entity characterised by the presence of mucinous ascites, omental cake, peritoneal implants and possibly ovarian involvement. It generally originates from mucinous appendiceal tumours. Content: This review details the clinical presentation of this unusual condition, presents the new classification system and how this relates to outcome. The pathophysiology of this disease is also explored with a special reference to the relationship of the disease to tumour markers. Summary: A classification system has been agreed upon by the leading experts in PMP which is now divided into low and high grade mucinous carcinomatosis peritonei. This distinction correlates with clinical outcome as does the presence of raised tumour markers preoperatively. Outlook: Research needs to be focused on understanding the factors associated with poor prognosis through well designed multi-centred prospective studies. This will allow us to identify patients with bad tumour biology so that targeted treatment based on likely prognosis may then become a reality.

Entities:  

Keywords:  HIPEC; appendiceal mucinous neoplasm; cytoreductive surgery; oncogenes; pseudomyxoma peritonei (PMP); tumour markers.

Year:  2016        PMID: 30911604      PMCID: PMC6386305          DOI: 10.1515/pp-2016-0008

Source DB:  PubMed          Journal:  Pleura Peritoneum        ISSN: 2364-768X


  2 in total

1.  Clinicopathological Characteristics of Primary Appendiceal Mucinous Neoplasm and Recurrence After Radical Resection.

Authors:  Zaibiao Wang; Manman Yin; Jiayun Shao; Zhipeng Yin; Jie Peng; Zhengmao Lu
Journal:  Front Surg       Date:  2022-05-04

2.  Unusual site of pseudomyxoma peritonei recurrence after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a case report of intraluminal disease manifestation in the small bowel.

Authors:  Paulien Rauwerdink; Lodewijk A A Brosens; Karin K van Diepen; Okan N Ghedri; Onno Kranenburg; Djamila Boerma; Arjen J Witkamp; Helma M U van Grevenstein
Journal:  World J Surg Oncol       Date:  2022-05-10       Impact factor: 3.253

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.